Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MARK3 | P27448 | 6/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | MARK4 | Q96L34 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25890242 | 0.83 | ADORA3 (0.37) | LMNAGAAKDM4EHCRTR1MAPT | |
| SCHEMBL28014458 | 0.81 | CRHR1 (0.37) | LMNAGAAMARK3PGRCRHR1 | |
| SCHEMBL8687319 | 0.81 | LMNA (0.35) | LMNAGAAKDM4EHCRTR1MAPT | |
| SCHEMBL28036739 | 0.81 | CRHR1 (0.37) | MARK3PGRCRHR1MARK4 | |
| SCHEMBL21993355 | 0.79 | EGLN1 (0.41) | MARK3BACE1 | |
| SCHEMBL9505759 | 0.79 | LMNA (0.35) | LMNAGAAMAPT | |
| SCHEMBL9470123 | 0.78 | MARK3 (0.51) | MARK3PGRCRHR1MARK4 | |
| SCHEMBL12990219 | 0.78 | PDK2 (0.36) | LMNAKDM4EHCRTR1MAPTL3MBTL1 | |
| SCHEMBL9469392 | 0.77 | PGR (0.56) | GAAMARK3PGR | |
| SCHEMBL31389178 | 0.76 | PDK2 (0.38) | LMNAGAAKDM4EHCRTR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | claimed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | claimed |
| US-5182289-A | Pyrrolo 2,3-b!Pyridin-2-one Derivatives | SCHERING CORPORATION (US) | 1993-01-26 | — | — | US | claimed |
| EP-0419561-A1 | HETEROBICYCLIC COMPOUNDS HAVING ANTIINFLAMMATORY ACTIVITY | SCHERING CORPORATION (US) | 1991-04-03 | — | — | EP | claimed |
| WO-1989012637-A1 | HETEROBICYCLIC COMPOUNDS HAVING ANTIINFLAMMATORY ACTIVITY | SCHERING CORPORATION (US) | 1989-12-28 | — | — | WO | claimed |
| EP-0347698-A1 | Heterobicyclic compounds having antiinflammatory activity | SCHERING CORPORATION (US) | 1989-12-27 | — | — | EP | claimed |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| US-5182289-A | Pyrrolo 2,3-b!Pyridin-2-one Derivatives | SCHERING CORPORATION (US) | 1993-01-26 | — | — | US | disclosed |
| EP-0419561-A1 | HETEROBICYCLIC COMPOUNDS HAVING ANTIINFLAMMATORY ACTIVITY | SCHERING CORPORATION (US) | 1991-04-03 | — | — | EP | disclosed |
| WO-1989012637-A1 | HETEROBICYCLIC COMPOUNDS HAVING ANTIINFLAMMATORY ACTIVITY | SCHERING CORPORATION (US) | 1989-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | LMNA 860/4885GAA 1201/4885MARK3 122/4885 |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | LMNA 860/4885GAA 1201/4885MARK3 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.